Melanoma is one of the few tumor types in which p53 is functionally repressed without extraneous mutations. With the number of kinase-based drug targets rapidly declining, p53 represents a relatively untapped resource for therapeutic intervention. Studies in other tumor types have demonstrated that reactivation of p53 is a viable strategy to initiate sustained tumor regression; combining p53 reactivation while inhibiting traditional genetic targets, such as mitogenactivated protein kinase/extracellular signal-related kinase kinase (MeK), holds therapeutic promise.
melanoma: current clinical outlook
The clinical success of vemurafenib (PLX4032) has underscored the importance of the mitogen-activated protein kinase (MAPK) signaling cascade in the initiation, progression, maintenance, and overall survival of malignant melanoma (Flaherty et al., 2010) . Excitement surrounding this success is somewhat tempered by the eventual relapse of melanoma patients (median progression-free survival is 7 months). Thus, there remains a legitimate need for second-generation treatment options for patients whose disease will eventually recur while receiving vemurafenib.
A surge of recent reports has demonstrated multiple mechanisms of acquired resistance to mutantspecific inhibitors of B-Raf such as vemurafenib (Poulikakos and Rosen, 2011) . Upregulation of the insulinlike growth factor receptor-1, de novo mutations in N-Ras, increased expression of the platelet-derived growth factor receptor-b, and increased activity of MAP3K8/Cot have been described as mechanisms employed by melanoma cells to bypass the proapoptotic activities of this class of inhibitors. Related studies have also shown that intrinsic resistance to B-Raf inhibitors is largely contingent on the expression of PTEN, the negative regulator of the phosphoinositide 3-kinase pathway (Gopal et al., 2010) , suggesting that activation of this pathway is sufficient to render melanoma cells innately resistant to mutant B-Raf inhibition. Collectively, these studies suggest that therapeutic regimens that combine MAPK inhibition with pharmacological manipulation of alternative molecular circuitry will be necessary to achieve sustained responses in the clinic.
Status of p53 signaling in melanoma
The frequency of p53 mutations in melanoma is dramatically lower than that in most other solid tumors, with inactivating mutations seen in less than 10% of patients. In contrast to its tumorsuppressive functions, p53, the "guardian of the genome," was originally reported to be overexpressed in melanoma (Albino et al., 1994) . Subsequent studies, however, have demonstrated that p53 function is largely repressed in melanoma via several mechanisms: (i) overexpression or amplification of the negative regulator of p53, HDM2, and (ii) the loss or silencing of the CDK2NA locus that encodes Arf, an antagonist of HDM2 function (Bennett, 2008) . These genetic events are seen in nearly 90% of patients with melanoma, suggesting that p53 inactivation plays a significant role in its etiology, despite the overt lack of mutations observed compared with many other tumor types.
In this issue, Ji et al., from Hensin Tsao's group, report the results of sequencing performed across a large panel of cell lines to explore further the status of p53 expression in malignant melanoma. They demonstrate that more than two-thirds of melanoma cell lines express wild-type p53; nearly 70% of p53 wild-type lines were shown to have genomic losses of the CDK2NA locus. In lines expressing mutant p53, 33% displayed similar losses, indicating that a large proportion of melanoma cell lines selectively lose this locus during melanoma development and/or in vitro establishment. These observations are supported by previous studies and underscore the critical role provided by ARF in modulating control over the p53 signaling pathway.
p53 reactivation therapy: hope or hype?
Traditional chemotoxic therapies activate p53 function via the accumulation of DNA damage and other stress-related pathways. The advent of targeted therapy introduced the notion of reactivating p53 in a nongenotoxic manner, thereby restoring its tumor-suppressive capacity without inducing additional mutations or unnecessary stress to the cell. Early attempts to restore p53 activity utilizing adenoviral vectors to deliver p53 have demonstrated clinical efficacy and are under further investigation. More recent research has focused on pharmacological reactivation of p53 through modulation of the activity of its multiple regulatory factors, including SirT1/2, CRM1, and MDM2. The most prominent members of this class of effector compounds are the Nutlins, antagonists of the MDM2-p53 interaction that initiates the proteasomal degradation of p53. RG7112, the most promising Nutlin drug candidate, is undergoing clinical evaluation in both solid and nonsolid malignancies. Ji et al. (2012) demonstrate in their work that the commercially available Nutlin-3 compound stabilizes p53 and increases its transcriptional activity. Additionally, they show that cell viability is most affected in melanoma cell lines expressing wild-type p53, as might be expected. The investigators subsequently hypothesized that, because the majority of melanoma patients harbor BRAF mutations yet express wild-type p53, this genotype (BRAF mut , p53 wt ) might best be targeted with a dual therapy involving MEK inhibition and p53 activation.
A therapeutic regimen in which inhibition of the MAPK cascade is combined with reactivation of p53 in malignant melanoma is certainly predicated on well-established genetic data. The MAPK signaling pathway is activated in nearly all melanomas, with the most prevalent activating mutations in BRAF, NRAS, and cKit. Likewise, as outlined above, nearly 90% of melanomas express wild-type, but functionally impaired, p53. Based on these observations, the investigators treated ~40 cell lines with a known MEK inhibitor (U0126), Nutlin-3, or a combination of the two compounds to determine their additive, antagonistic, or synergistic effects. The results from these studies demonstrated that ~60% of melanoma cell lines exhibit some degree of synergy, whereas the remaining portion (38%) appear to have antagonistic effects after coadministration of U0126 and Nutlin-3. The antagonism observed in such a large percentage of melanomas argues for additional studies to determine why such contrasting effects are exhibited within a single cancer type. Ji et al. suggest that prospectively genotyping patients should help stratify responders from nonresponders, but more exploration is necessary to explain this phenomenon.
Similar reports outlining the use of pharmacological p53 activators in melanoma have described a diverse response that can range from cell cycle arrest to induction of apoptosis to no response at all (Terzian et al., 2010) . To achieve measurable clinical responses in human patients, however, the general goal is to induce cell death or apoptosis consistently. Earlier data suggested that nearly two-thirds of melanoma lines responded favorably to combined MEK inhibition and p53 activation; Ji et al. (2012) therefore investigated the induction of caspase activity and dependence of apoptotic induction on p53 after treatment with this same drug combination. Their results argue that the loss of viability observed in earlier experiments is due largely to a p53-dependent induction of caspase-3/7 activity. These data support the development of therapeutic strategies that target these pathways to achieve similar effects in humans.
mechanistic explanations
Melanoma is a bona fide example of a cancer exhibiting oncogene addiction, in which inhibition of the initiating oncogene kills transformed cells. However, most studies investigating MEK inhibitors have described a cytostatic, rather than cytotoxic, effect when using this class of compounds (Haass et al., 2008) . Furthermore, p53 reactivation in melanoma has been reported to inhibit cell cycle progression with only moderate induction of apoptosis in selected cells (Terzian et al., 2010) . Therefore, it is exciting to speculate about the mechanisms by which these generally cytostatic compounds become cytotoxic after concurrent administration. One plausible explanation is that MEK inhibition initiates transcriptional and posttranscriptional downregulation of the HDM2 gene, leading to decreased HDM2 protein levels and increased p53 activity (Phelps et al., 2005) . Alternatively, other groups have reported that p53-mediated apoptosis is dependent on Arf, a protein encoded by the CDK2NA locus that is often deleted in malignant melanomas, particularly in established cell lines such as those used in the current study (Junttila et al., 2010) ; it would therefore be intriguing to first stratify the melanoma lines based on their expression of the CDK2NA locus and then ascertain their single and combined responsiveness to these agents to help identify genetic-based prognostic indicators of response.
outlook and directions
Approximately 1 in 25 Americans will acquire some type of cancer in his or her lifetime; of these, a smaller percentage will be diagnosed with melanoma. The human body has a remarkable capacity to prevent, circumvent, and otherwise fight the initiation and progression of malignancies, as evidenced by the 96% of the population who will die cancer free. This observation underscores the extraordinary success rate of tumor suppressors such as p53 to continually survey the body for biological stresses that ultimately damage DNA and selectively destroy those rogue cells.
Restoring the ability of p53 in malignant cells is an exciting approach for melanoma and broader cancer therapeutics. Selectively targeting the kinome is highly regarded for its relevance in cancer, as well as its druggability; however, there are valid concerns surrounding the feasibility of selectively modulating transcription factors such as p53, including regulation of essential downstream gene effectors. That said, there are a large number of nongenotoxic pharmacological activators of p53 in the Clinical Implications preclinical and clinical pipeline with multiple mechanisms of action (Chen et al., 2010) that may help discern the subtle nuances that ultimately dictate the cellular outcome (cytostatic versus cytotoxic) to p53 reactivation. Combining such therapies with inhibition of the MAPK pathway is logical and predicated on well-established clinical observations. Thus, Ji and colleagues' report provides a solid platform on which future experimentation can be devised to delve into the molecular circuitry that predicts responses to this type of therapy.
